Gasherbrum Bio, Inc., A Wholly Owned Subsidiary Of Structure Therapeutics

This study tests a new daily pill, aleniglipron, in 58 adults with type 2 diabetes who are overweight or obese. The main goal is to check if the drug is safe and tolerable at different doses. Researchers will also measure weight loss and blood sugar changes. The study is not yet …

This study tests an experimental daily pill called aleniglipron for weight loss in 220 adults with obesity or overweight who also have a weight-related health issue. Participants receive either the drug or a placebo for 36 weeks, with the option to continue on the drug for anothe…

This study tests a new oral drug called aleniglipron (GSBR-1290) in 71 adults with obesity (BMI ≥30). Participants take the drug or a placebo daily for 40 weeks. Researchers measure changes in body fat, waist size, and weight using special scans. The goal is to see if the drug sa…